Keros Therapeutics, Inc. (KROS) saw a significant decline in its stock price on December 17, 2024, closing at $18.00, down 7.31% from the previous day's close of $19.42. The stock opened at $19.33 and reached a high of $19.40 before dropping to a low of $17.80. The trading volume was notably high at 2,211,186 shares, over three times the average daily volume, indicating heightened investor activity. The sha
Keros Therapeutics is experiencing a decline in its stock price today following the company's decision to halt higher doses in a lung disease study due to side effects. This development, which was reported on December 17, 2024, has raised concerns among investors about the potential impact on the company's pipeline and future prospects. The decision to stop administering higher doses in the study of ciboter
Keros Therapeutics, Inc. (KROS) saw its stock rise by 3.13% to close at $19.42 on December 16, 2024, despite a turbulent day marked by significant trading volume, which was 281.70% above the average. The stock opened at $18.25, dipped to a low of $18.08, and reached a high of $19.65. The day's movement was influenced by a series of analyst actions and investor reactions. Notably, Oppenheimer lowered its pri
Keros Therapeutics, Inc. (KROS) has been a topic of discussion on Reddit following a downgrade by Guggenheim. The downgrade has sparked conversations among investors, with some expressing concern over the potential implications for the company's future performance. The lack of specific news detailing the reasons behind the downgrade has left room for speculation among the community.
On Reddit, users are ac
Keros Therapeutics, Inc. (KROS) saw a notable increase in its stock price on December 13, 2024, closing at $18.83, up 2.17% from the previous day's close of $18.43. The stock opened at $18.76 and reached an intraday high of $21.05 before settling down. This surge in price was driven by Wells Fargo's decision to raise its price target for Keros from $11 to $28, reflecting increased confidence in the company'
Keros Therapeutics (KROS) is experiencing a significant decline in its stock price today following the announcement of a voluntary halt in dosing for two treatment arms in its Phase 2 TROPOS trial. The decision was made after a safety review revealed unanticipated pericardial effusion adverse events in the trial, which is evaluating cibotercept for pulmonary arterial hypertension. This development has raise
Keros Therapeutics (KROS) is experiencing a notable rise in its stock price following a significant development from Wells Fargo. The investment bank raised its price target for Keros Therapeutics by $17, signaling increased confidence in the company's future prospects. This adjustment comes amid ongoing developments in Keros' clinical trials, particularly the TROPOS trial, which is evaluating the efficacy
Keros Therapeutics has faced a significant setback after halting dosing in two of the three treatment arms of its phase 2 TROPOS trial for the pulmonary arterial hypertension (PAH) drug, cibotercept. The decision was made following reports of pericardial effusion, a condition involving fluid buildup around the heart, in patients receiving the higher doses of 3 mg/kg and 4.5 mg/kg. This unexpected safety con
Keros Therapeutics has experienced a dramatic decline in its stock price following the announcement of a halt in higher dosing for its lung disease drug trial. The decision to pause the trial was made after safety concerns emerged, which have raised significant apprehension among investors regarding the future of the drug's development. The halted trial was a critical component of Keros' pipeline, and the u
Keros Therapeutics, Inc. (KROS) is experiencing a rise in its stock price in pre-market trading on December 6, 2024. This movement comes as research analysts at Wedbush have increased their earnings estimates for the company. The updated forecast for Keros' Q1 2025 earnings is now set at ($1.40) per share, an improvement from the previous estimate of ($1.44). Wedbush maintains an "Outperform" rating on the
Keros Therapeutics, Inc. (KROS) has seen a positive movement in its stock price following the announcement of a significant global license agreement with Takeda. On December 3, 2024, Keros disclosed that it would receive a $200 million upfront payment from Takeda, with the potential for additional milestone payments exceeding $1.1 billion. This agreement grants Takeda the exclusive rights to develop, manufa
Keros Therapeutics (KROS) shares are experiencing a significant uptick following the announcement of a global licensing agreement with Takeda Pharmaceuticals. Under the terms of the deal, Keros will receive a $200 million upfront payment and is eligible for additional milestone payments that could exceed $1.1 billion, along with tiered royalties on net sales. This agreement grants Takeda the rights to devel
Keros Therapeutics, Inc. has announced a significant global licensing agreement with Takeda to advance the development and commercialization of elritercept, a drug currently in Phase 2 clinical trials for myelodysplastic syndrome (MDS) and myelofibrosis (MF). Under the terms of the agreement, Keros will receive a $200 million upfront payment and is eligible for additional milestone payments that could excee
Keros Therapeutics, Inc. (KROS) is experiencing a decline in its stock price today, which may be attributed to recent changes in institutional ownership. Quest Partners LLC significantly reduced its stake in the company by 86.9% during the third quarter, as reported in a recent filing with the Securities & Exchange Commission. This reduction involved selling 4,177 shares, leaving Quest Partners with only 63
Keros Therapeutics, Inc. (KROS) shares are experiencing an uptick today, likely influenced by recent institutional interest. Alkeon Capital Management LLC significantly increased its stake in the company by 18.7% during the third quarter, as reported in a recent SEC filing. This move by a major institutional investor may have bolstered market confidence in Keros, contributing to the stock's upward momentum.